Lilly's Sarcoma Drug Likely To Be Used Widely Despite EU Conditional OK

The promise seen in Lartruvo, Lilly’s new drug for the rare condition soft tissue sarcoma, should offset payer and HTA reluctance to use the monoclonal antibody despite its conditional EU marketing approval status.